News + Font Resize -

NPIL inks 5-yr deal with Genzyme Corp
Our Bureau, Mumbai | Thursday, August 5, 2004, 08:00 Hrs  [IST]

Nicholas Piramal India Limited has completed its in-licensing agreement with Genzyme Corporation, USA for Synvisc Viscose Supplementation for the Indian market.

It is believed that the five-year alliance is poised to augment NPIL's presence in the field of orthopedics.

Genzyme Corporation, Cambridge, USA, which is the 4th largest biotech company with a revenue base of $1.6 billion, has a strong presence in the fields of orthopedics, renal diseases, lisosomal storage disorders and Adhesion prevention.

The product has global sales of US$ 250 million and the Indian market size for this drug is estimated at Rs 20 crore. NPIL will market & distribute the product in India on exclusive basis, the release added.

Synvisc is a therapy for the local treatment of pain associated with osteoarthritis (OA) of the knee. It is a pill-free treatment that is injected directly into the knee. Successful treatment with Synvisc can help reduce or stop pain in an osteoarthritic knee, may increase mobility, and may allow for a higher and more comfortable level of activity.

Currently, NPIL's Ortho-therapy area includes two divisions - MS and Speciality (a division of the erstwhile Sarabhai Piramal Pharmaceuticals Pvt. Ltd.). NPIL leading brands include Vah, Valto, Rejoint, Rocaltrol, Esgipyrin, Biozobid rang, Suganril range and Contramal.

Post Your Comment

 

Enquiry Form